The biological stage for this debate is set by glial cells. Although the blood-brain barrier grants the central nervous system a degree of immune privilege, the brain is actively patrolled by resident immune cells, principally microglia and astrocytes. Under healthy conditions these cells maintain tissue homeostasis, but when they detect danger signals they become the innate immune effectors of the brain, amplifying or resolving inflammatory responses. LPS engages this machinery with surgical precision: it binds Toll-like receptor 4 in cooperation with the co-receptors CD14 and MD-2, igniting a canonical signalling cascade that culminates in the production of tumour necrosis factor-alpha, interleukin-1beta, interleukin-6, nitric oxide via inducible nitric oxide synthase, and reactive oxygen species. When this activation is acute it can be adaptive, but sustained glial activation drives oxidative and nitrosative stress, and chronic microglial mediators can even push astrocytes into reactive states that erode neuronal support.

The problem, according to the review, is heterogeneity. LPS preparations differ in bacterial source, serotype, chemotype and purification grade, and studies vary wildly in dose, exposure duration, route of administration and the timing of their measurements. In vitro, most work relies on murine microglial systems, particularly the immortalised BV-2 and N9 lines and primary microglia, with LPS concentrations typically spanning 100 nanograms to 1 microgram per millilitre. Signalling switches on within minutes to hours, yet many studies sample only at 24 to 48 hours, when the biology has already moved on. The authors argue that early signalling events, such as phosphorylation of IKBalpha and nuclear translocation of the transcription factor NF-kappaB p65, are most informative within the first two hours, while later outputs like nitric oxide accumulation, prostaglandin E2 release and cytokine secretion reflect transcriptional and phenotype-level changes best captured between 12 and 48 hours. Sampling at the wrong moment conflates these distinct phases and weakens mechanistic attribution.

To build their framework, the authors conducted a structured search of PubMed, Scopus and Web of Science covering English-language publications from 2010 to 2026, ultimately synthesising evidence from 50 unique studies of isolated phytochemicals and chemically characterised natural products tested in LPS-induced neuroinflammation models. The readout landscape they map is dominated by nitric oxide biology, with nitrite quantification and iNOS induction serving as screening anchors, flanked by cytokine panels, COX-2 and prostaglandin E2 measurements, oxidative stress markers such as glutathione ratios and mitochondrial reactive oxygen species, and an essential layer of viability assays including MTT, CCK-8 and lactate dehydrogenase release to exclude non-specific cytotoxic suppression. Some studies go further, tracking microglial activation markers like Iba-1 and CD68, phagocytosis, morphology, and metabolic signatures such as extracellular acidification and oxygen consumption rates.

Mechanistically, the reviewed evidence converges on a surprisingly restricted set of signalling modules. NF-kappaB-centred signalling is the most frequently interrogated layer, assessed through p65 phosphorylation, nuclear translocation and DNA-binding activity. MAPK cascades involving ERK, JNK and p38, along with PI3K-Akt signalling, are profiled as complementary readouts. A subset of studies extends into NLRP3 inflammasome territory, measuring caspase-1 activation, gasdermin D cleavage and mature interleukin-1beta release, while others position compounds within the Nrf2-HO-1 antioxidant axis, mitophagy markers like PINK1 and Parkin, or immunometabolic nodes such as the glycolytic enzyme PKM2 and its transcriptional partner HIF-1alpha. Secondary regulatory modules, the authors stress, modulate the magnitude and resolution of the core LPS response rather than acting as primary sensing pathways, a distinction that matters when interpreting what a compound is actually doing.

The review illustrates this mechanistic positioning with concrete examples. Quercetin, tested in BV-2 microglia exposed to 100 nanograms per millilitre of LPS, reduced inflammatory cytokines and reactive oxygen species while suppressing NLRP3, cleaved caspase-1 and gasdermin D, and increasing PINK1 and LC3-II, pointing to a coupling between inflammasome control and mitochondrial quality assurance. In mice receiving repeated LPS injections, quercetin reduced hippocampal and cortical Iba-1 and CD68 and lowered immobility in behavioural tests. Sulforaphane offers a different pattern: in primary microglia it reduced TNF-alpha and interleukin-1beta within a PI3K-Akt activation framework, and in mice it alleviated depression-like behaviour in a manner abolished by pharmacological Akt inhibition. Coptisine, meanwhile, was positioned at the immunometabolic interface, reducing phosphorylated PKM2, nuclear PKM2 and HIF-1alpha, and attenuating anxiety-like behaviour in vivo.

On the animal side, the review finds that systemic intraperitoneal LPS administration predominates in rodents, with single doses ranging from 100 micrograms to 6 milligrams per kilogram and repeated schedules extending up to 14 days, while intracerebroventricular delivery and zebrafish models provide complementary spatial and kinetic insights. But the authors flag a critical interpretive caveat: systemic LPS engages peripheral immune signalling and sickness-like physiology, so it cannot be read as isolated brain inflammation. Stronger central attribution requires brain-region-specific inflammatory, glial or neuronal readouts, typically from hippocampus and cortex, alongside systemic measures. They also highlight a persistent blind spot in the literature: most rodent studies use male animals only, even though immune signalling and microglial activation are sex-dependent, potentially limiting generalisability.

To bring order to this heterogeneous evidence base, the authors propose a pragmatic four-level hierarchy of claim strength. Level 1, preliminary, covers viability-controlled changes in inflammatory markers in a single model. Level 2, mechanistic, requires concordant early-signalling and downstream mediator changes supported by replication or dose-response evidence. Level 3, cross-model, demands multi-endpoint confirmation in an independent, primary, human-relevant or multicellular platform, and is proposed as the decision point for considering progression to animal studies. Level 4, preclinical, requires coherent in vitro and in vivo findings including brain inflammatory or glial endpoints together with functional outcomes. Crucially, behaviour-only animal findings do not automatically qualify as Level 4 evidence, and studies sharing the same methodological limitations do not compound confidence.

The translational stakes are considerable. Plant-derived compounds remain a rich source of candidate anti-inflammatory agents, but the authors caution that a compound showing only nitric oxide or cytokine suppression in a single immortalised microglial line should be considered a preliminary screening hit at best. Stronger candidates link mediator suppression to pathway engagement under viability control, and the most promising ones show multi-endpoint activity across primary or human-relevant systems and animal models with brain-region and behavioural readouts. Looking forward, they call for human iPSC-derived microglia, microglia-containing organoids, microfluidic blood-brain barrier platforms and multicellular co-cultures to replace reliance on immortalised lines, and for inflammasome studies to distinguish LPS priming from secondary activation signals such as ATP, so that compound effects can be attributed to specific steps rather than the cascade as a whole.

The review also confronts an uncomfortable possibility: publication bias. Positive phytochemical findings may be preferentially published over neutral, negative or toxicity results, and testing multiple compounds, concentrations and endpoints can overstate consistency across models. Because this was a narrative review rather than a formal systematic one, the extent of such bias cannot be quantified, but the authors urge prespecified endpoints and honest reporting of null findings. Their bottom line is a call for discipline: standardised reporting of LPS source, serotype, purity, dose, timing and route; endpoints matched to inflammatory kinetics; validation in biologically distinct platforms; and cautious interpretation that treats positive results as evidence of pathway modulation under a defined challenge rather than proof of disease-modifying efficacy. In a field racing to find natural defenders of the brain, the most powerful tool may simply be a stopwatch.

Subject of Research: Lipopolysaccharide-induced neuroinflammation models and their use in phytochemical screening for anti-inflammatory drug discovery

Article Title: Kinetics and mechanisms in lipopolysaccharide-induced neuroinflammation: a framework for phytochemicals screening

Article References: Kinetics and mechanisms in lipopolysaccharide-induced neuroinflammation: a framework for phytochemicals screening. (n.d.). https://doi.org/10.1007/s11033-026-12817-4

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12817-4

Keywords: neuroinflammation, lipopolysaccharide, microglia, TLR4, NF-kappaB, phytochemicals, NLRP3 inflammasome, Nrf2, BV-2 cells, cytokines, blood-brain barrier, experimental design

One of the most compelling advancements involves a newly developed positron emission tomography (PET) radioligand known as ^11C-ZTP-1, which specifically targets phosphodiesterase 4B (PDE4B) — an enzyme intricately connected to neuroinflammation and various neuropsychiatric disorders. The ability of ^11C-ZTP-1 to selectively image PDE4B was rigorously validated in preclinical models including rats and non-human primates. This short-lived radiotracer’s unique properties facilitate the possibility of multiple scans within the same day, an innovation that could accelerate both fundamental brain research and the clinical development pipeline for novel neurotherapeutics by providing dynamic, temporal mapping of enzyme activity in vivo.

Expanding our understanding of breast cancer imaging, another pioneering study challenges the traditional categorization of “false positives” in PET imaging by utilizing ^89Zr-labeled antibodies. This approach has demonstrated the capacity to detect HER2-low breast cancer lesions, a subset formerly misclassified and overlooked due to limitations of earlier imaging modalities. This revelation not only broadens the diagnostic scope of HER2 PET imaging but also introduces the potential for identifying patients who could benefit from emerging HER2-targeted therapies, representing a paradigm shift in oncological precision medicine that prioritizes molecular heterogeneity.

Further enhancements in brain imaging are demonstrated by the introduction of ^18F-K-40, a novel PET tracer that permits visualization of AMPA receptors in living human subjects. AMPA receptors, fundamental to excitatory neurotransmission and synaptic plasticity, play a pivotal role in cognitive processes and neurological health. By matching the specificity and sensitivity of prior tracers with the added advantage of a longer half-life, ^18F-K-40 enables more flexible and accessible imaging protocols, promising to deepen investigations into neurological and psychiatric diseases where AMPA receptor dysfunction is implicated, such as epilepsy, depression, and neurodegeneration.

In a separate investigation, whole-body PET imaging using ^11C-carfentanil, a selective agonist for μ-opioid receptors, has unveiled significant sex-based differences in receptor distribution and naloxone-mediated receptor blockade within the central nervous system. By capturing the nuanced neurobiological variations between men and women in brain regions associated with pain modulation and addiction, this study provides critical insights that could inform sex-specific strategies for managing opioid use disorder and improving the efficacy of analgesic therapies. Understanding these distinctions enhances our grasp of opioid pharmacodynamics and may lead to more personalized approaches in pain medicine and addiction treatment.

Parallel to these empirical studies, a comprehensive review articulates the expanding role of molecular imaging in human phenomics—the systemic study of phenotypes at a complexity scale. Integrating molecular imaging with multiomics datasets and artificial intelligence (AI), this research underscores the transformative potential of such synergy to offer quantitative, predictive insights. This systems-level approach moves beyond traditional diagnostics, fostering preclinical intervention strategies and facilitating a precision health framework centered on individualized biological complexity and continuous monitoring.

The frontiers of personalized cancer imaging and therapy are also pushed forward through investigations targeting the gastrin-releasing peptide receptor (GRPR). Recognized for its overexpression in multiple tumors, GRPR stands as a promising biomarker and therapeutic target. The transition from bench to bedside is explored, emphasizing the dual role of GRPR-based molecular imaging in both diagnosing diverse cancers and delivering targeted radionuclide therapy. This approach embodies the principles of theranostics, thereby optimizing patient selection and therapeutic efficacy while minimizing off-target effects.

Collectively, these studies exemplify a multifaceted advancement of nuclear medicine, leveraging sophisticated tracer chemistry, enhanced imaging techniques, and system biology approaches to drive forward precision medicine. The implications extend from improved brain disorder management and cancer therapeutics to refined diagnostic accuracy, establishing new standards for molecular imaging’s integration into clinical workflows. These innovations hint at a future where individualized treatment selection and comprehensive phenomic assessment are hallmarks of patient care.

Moreover, these pioneering PET imaging tools highlight a key shift toward creating tracers tailored not only for improved diagnostic clarity but also for enabling dynamic therapeutic monitoring. The ability to visualize enzymatic activity, receptor binding, and cellular heterogeneity in vivo opens unparalleled avenues for drug development, patient stratification, and real-time treatment assessment, cultivating an era of truly personalized medicine underpinned by actionable molecular insights.

Advancements in whole-body imaging, such as those achieved with ^11C-carfentanil, demonstrate the feasibility of moving beyond regional brain studies to systems-level interrogation of receptor distributions and pharmacokinetics. This approach facilitates a holistic understanding of complex biological systems and sexes differences, which are often underappreciated in neuropharmacology—offering fertile ground for new discoveries that properly integrate biological diversity into therapeutic design.

The integration of artificial intelligence and multiomics into molecular imaging reveals an exciting interdisciplinary frontier, exploiting the vast data generated through imaging technologies to create predictive models and refined diagnostics. This bidirectional relationship harnesses AI’s capacity to decode complex imaging patterns, while molecular imaging provides the spatially and temporally dense data necessary for nuanced model training—a symbiosis poised to revolutionize predictive medicine, early disease detection, and personalized intervention strategies.

As the field advances, the translational pipeline for molecular imaging agents such as those targeting PDE4B and GRPR is essential for transforming laboratory discoveries into clinical realities. Accelerating regulatory approval, expanding accessibility, and ensuring cost-effectiveness remain challenges, yet the potential impact on patient diagnosis, treatment personalization, and outcome prediction affirms the immense value of these innovations for modern healthcare systems.

The Journal of Nuclear Medicine continues to be at the forefront of disseminating pivotal research that redefines our approach to molecular diagnostics and therapeutics. With a global audience exceeding 15 million annual accesses, the journal serves as an indispensable resource for clinicians, researchers, and industry stakeholders dedicated to harnessing nuclear medicine’s potential to improve patient lives.

For the latest in molecular imaging advancements, practitioners and researchers are encouraged to explore JNM’s comprehensive coverage as the field moves toward increasingly sophisticated, integrative, and patient-specific methodologies that stand to reshape the landscape of healthcare.

Subject of Research: Molecular imaging innovations in neuroscience, oncology, and precision health

Article Title: Various – including “New Brain Imaging Tool Targets Key Enzyme in Mental Health” and “Targeting GRPR: A New Frontier in Personalized Cancer Imaging and Therapy”

News Publication Date: May 9, 2025

Web References:
https://doi.org/10.2967/jnumed.124.269159
https://doi.org/10.2967/jnumed.124.269227
https://doi.org/10.2967/jnumed.124.269405
https://doi.org/10.2967/jnumed.124.269413
https://doi.org/10.2967/jnumed.124.267660
https://doi.org/10.2967/jnumed.124.269444

Keywords: Molecular imaging, PET tracers, PDE4B, HER2-low breast cancer, AMPA receptors, μ-opioid receptors, GRPR, precision medicine, theranostics, neuropsychiatric disorders, molecular phenomics, sex differences, multiomics, artificial intelligence